Efficacy and safety of daptomycin for the treatment of infectious disease: A meta-analysis based on randomized controlled trials

Journal of Antimicrobial Chemotherapy

Volumn 69, Issue 12, 2014, Pages 3181-3189

  He, Wenqiang ^a   Zhang, Yawei ^a   Chen, Hongbin ^a   Zhao, Chunjiang ^a   Wang, Hui ^a  

^a PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

Author keywords

CPK elevation; Lipopeptides; Renal impairment

Indexed keywords

CREATINE KINASE; DAPTOMYCIN; VANCOMYCIN; ANTIINFECTIVE AGENT;

ARTICLE; CONSTIPATION; CREATINE KINASE BLOOD LEVEL; DIARRHEA; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; HEADACHE; HUMAN; INCIDENCE; INFECTION; KIDNEY DISEASE; META ANALYSIS; MORTALITY; NAUSEA; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; TREATMENT DURATION; ADULT; AGED; BLOOD; COMMUNICABLE DISEASES; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; MALE; MIDDLE AGED; PATHOLOGY; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; COMMUNICABLE DISEASES; CREATINE KINASE; DAPTOMYCIN; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84926472281     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dku277     Document Type: Article

References (45)

1. Alemayehu D, Quinn J, Cook J et al. A paradigm shift in drug development for treatment of rare multidrug-resistant Gram-negative pathogens. Clin Infect Dis 2012; 55: 562-7.
2. Carpenter CF, Chambers HF. Daptomycin: another novel agent for treating infections due to drug-resistant Gram-positive pathogens. Clin Infect Dis 2004; 38: 994-1000.
3. Silverman JA, Perlmutter NG, Shapiro HM. Correlation of daptomycin bactericidal activity and membrane depolarization in Staphylococcus aureus. Antimicrob Agents Chemother 2003; 47: 2538-44.
4. Vilhena C, Bettencourt A. Daptomycin: a review of properties, clinical use, drug delivery and resistance. Mini Rev Med Chem 2012; 12: 202-9.
5. Sakoulas G. Clinical outcomes with daptomycin: a post-marketing, realworld evaluation. Clin Microbiol Infect 2009; 15 Suppl 6: 11-6.
6. Pertel PE, Bernardo P, Fogarty C et al. Effects of prior effective therapy on the efficacy of daptomycin and ceftriaxone for the treatment of community-acquired pneumonia. Clin Infect Dis 2008; 46: 1142-51.
7. Arbeit RD, Maki D, Tally FP et al. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis 2004; 38: 1673-81.
8. Fowler VG Jr, Boucher HW, Corey GR et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 2006; 355: 653-65.
9. Higgins JPT, Green S (eds). Cochrane Handbook for Systematic Reviews of Interventions, Version 5.1.0. The Cochrane Collaboration, 2011. http://www.cochrane-handbook.org (25 January 2013, date last accessed).
10. Martyn-St James M, Carroll S. Meta-analysis ofwalking for preservation of bone mineral density in postmenopausal women. Bone 2008; 43: 521-31.
11. Kanj SS, Chahoud J, Kanafani ZA. Right-sided infective endocarditis with pulmonary infiltrates. Int J Antimicrob Agents 2013; 42: S40.
12. Kanafani ZA, Kourany WM, Fowler VG Jr et al. Clinical characteristics and outcomes of diabetic patients with Staphylococcus aureus bacteremia and endocarditis. Eur J Clin Microbiol Infect Dis 2009; 28: 1477-82.
13. Krige JE, Lindfield K, Friedrich L et al. Effectiveness and duration of daptomycin therapy in resolving clinical symptoms in the treatment of complicated skin and skin structure infections. Curr Med Res Opin 2007; 23: 2147-56.
14. Lalani T, Boucher HW, Cosgrove SE et al. Outcomes with daptomycin versus standard therapy for osteoarticular infections associated with Staphylococcus aureus bacteraemia. J Antimicrob Chemother 2008; 61: 177-82.
15. Lipsky BA, Stoutenburgh U. Daptomycin for treating infected diabetic foot ulcers: evidence from a randomized, controlled trial comparing daptomycin with vancomycin or semi-synthetic penicillins for complicated skin and skin-structure infections. J Antimicrob Chemother 2005; 55: 240-5.
16. Rehm S, Campion M, Katz DE et al. Community-based outpatient parenteral antimicrobial therapy (CoPAT) for Staphylococcus aureus bacteraemia with or without infective endocarditis: analysis of the randomized trial comparing daptomycin with standard therapy. J Antimicrob Chemother 2009; 63: 1034-42.
17. Rehm SJ, Boucher H, Levine D et al. Daptomycin versus vancomycin plus gentamicin for treatment of bacteraemia and endocarditis due to Staphylococcus aureus: subset analysis of patients infected with methicillin-resistant isolates. J Antimicrob Chemother 2008; 62: 1413-21.
18. Kanafani ZA, Kourany WF, Levine DP et al. Clinical characteristics and outcome of patients with diabetes mellitus (DM) who develop Staphylococcus aureus bacteremia (SAB) and endocarditis (SAIE): results from the Daptomycin SAB SAIE trial. Clinical Research in Cardiology 2007; 96: 438.
19. Kanafani ZAL. Daptomycin for the treatment of infective endocarditis: results from a randomized trial comparing daptomycin to standard therapy for Staphylococcus aureus bacteremia and infective endocarditis. Clinical Research in Cardiology 2007; 96: 423.
20. Cosgrove SE, Vigliani GA, Fowler VG Jr et al. Initial low-dose gentamicin for Staphylococcus aureus bacteremia and endocarditis is nephrotoxic. Clin Infect Dis 2009; 48: 713-21.
21. Carugati M, Bayer AS, Miro JM et al. High-dose daptomycin therapy for left-sided infective endocarditis: a prospective study fromthe international collaboration on endocarditis. Antimicrob Agents Chemother 2013; 57: 6213-22.
22. Byren I, Wheeler A, Campanaro E et al. Phase 2 prospective randomised study investigating daptomycin 6 and 8 mg/kg versus standard antibiotic therapy in the treatment of staphylococcal prosthetic joint infections. Clin Microbiol Infect 2011; 17 Suppl 4: S821-2.
23. Konychev A, Heep M, Moritz RKC et al. A comparative randomised clinical trial against semi-synthetic penicillins and glycopeptides supports the use of daptomycin as first-line treatment of complicated skin and softtissue infections in the elderly. Clin Microbiol Infect 2012; 18 Suppl 3: 838-9.
24. Gollnick H, Fierlbeck G, Seaton RA et al. Efficacy and safety of daptomycin versus vancomycin or teicoplanin for the treatment of complicated skin and soft tissue infections: a multicentre, randomized, assessor-blind trial. Clin Microbiol Infect 2010; 16 Suppl 2: S450.
25. Shaw GJ, Meunier JM,Wayne BD et al. Evaluation of daptomycin for the emergency department treatment of cellulitis. Academic Emergency Medicine 2014; 21: S50.
26. Bhavnani SM, Rubino CM, Ambrose PG et al. Daptomycin exposure and the probability of elevations in the creatine phosphokinase level: data from a randomized trial of patients with bacteremia and endocarditis. Clin Infect Dis 2010; 50: 1568-74.
27. Kanafani Z, Boucher H, Fowler V et al. Daptomycin compared to standard therapy for the treatment of native valve endocarditis. Enferm Infecc Microbiol Clin 2010; 28: 498-503.
28. Katz DE, Lindfield KC, Steenbergen JN et al. A pilot study of high-dose short duration daptomycin for the treatment of patients with complicated skin and skin structure infections caused by Gram-positive bacteria. Int J Clin Pract 2008; 62: 1455-64.
29. Konychev A, Heep M, Moritz RKC et al. A comparative randomised clinical trial against semisynthetic penicillins and glycopeptides supports the use of daptomycin as first-line treatment of complicated skin and softtissue infections in the elderly. Clin Microbiol Infect 2012; 18: 838-9.
30. Naber KG, Eisenstein BI, Tally FP. Daptomycin versus ciprofloxacin in the treatment of complicated urinary tract infection due to Gram-positive bacteria. Infect Dis Clin Prac 2004; 12: 322-7.
31. Pertel PE, Eisenstein BI, Link AS et al. The efficacy and safety of daptomycin vs. vancomycin for the treatment of cellulitis and erysipelas. Int J Clin Pract 2009; 63: 368-75.
32. Quist SR, Fierlbeck G, Seaton RA et al. Comparative randomised clinical trial against glycopeptides supports the use of daptomycin as first-line treatment of complicated skin and soft-tissue infections. Int J Antimicrob Agents 2012; 39: 90-1.
33. Aikawa N, Kusachi S, Mikamo H et al. Efficacy and safety of intravenous daptomycin in Japanese patients with skin and soft tissue infections. J Infect Chemother 2013; 19: 447-55.
34. Byren I, Rege S, Campanaro E et al. Randomized controlled trial of the safety and efficacy of daptomycin versus standard-of-care therapy for management of patients with osteomyelitis associated with prosthetic devices undergoing two-stage revision arthroplasty. Antimicrob Agents Chemother 2012; 56: 5626-32.
35. Evers R, Antony NI, Alozie O et al. Pilot study comparing daptomycin and telavancin in the treatment of skin and soft tissue infections. Int J Infect Diseases 2013; 12: 2.
36. Sader HS, Jones RN. The activity of daptomycin against wild-type Staphylococcus aureus and strains with reduced susceptibility to vancomycin. Clin Infect Dis 2006; 43: 798-9; author reply 799-800.
37. Rege S, Mohr J, Lamp KC et al. Safety of daptomycin in patients completing more than 14 days of therapy: results fromthe CubicinwOutcomes Registry and Experience. Int J Antimicrob Agents 2013; 41: 421-5.
38. Falcone M, Russo A, Venditti M et al. Considerations for higher doses of daptomycin in critically ill patients with methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 2013; 57: 1568-76.
39. Cohen E, Dadashev A, Drucker M et al. Once-daily versus twice-daily intravenous administration of vancomycin for infections in hospitalized patients. J Antimicrob Chemother 2002; 49: 155-60.
40. Davis SL, McKinnon PS, Hall LM et al. Daptomycin versus vancomycin for complicated skin and skin structure infections: clinical and economic outcomes. Pharmacotherapy 2007; 27: 1611-8.
41. Falagas ME, Giannopoulou KP, Ntziora F et al. Daptomycin for treatment of patients with bone and joint infections: a systematic review of the clinical evidence. Int J Antimicrob Agents 2007; 30: 202-9.
42. Moise PA,Amodio-Groton M, RashidMet al. Multicenter evaluation of the clinical outcomes of daptomycin with and without concomitant b-lactams in patients with Staphylococcus aureus bacteremia and mild to moderate renal impairment. Antimicrob Agents Chemother 2013; 57: 1192-200.
43. Dvorchik BH, Brazier D, DeBruin MFet al. Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects. Antimicrob Agents Chemother 2003; 47: 1318-23.
44. Murray KP, Zhao JJ, Davis SL et al. Early use of daptomycin versus vancomycin for methicillin-resistant Staphylococcus aureus bacteremia with vancomycin minimum inhibitory concentration.1 mg/L: a matched cohort study. Clin Infect Dis 2013; 56: 1562-9.
45. Moore CL, Osaki-Kiyan P, Haque NZ et al. Daptomycin versus vancomycin for bloodstream infections due to methicillin-resistant Staphylococcus aureus with a high vancomycin minimuminhibitory concentration: a casecontrol study. Clin Infect Dis 2012; 54: 51-8.